DLL3 and cancer: Successful preclinical NIR-PIT studies against cancer and cancer-stem like cell antigens have been performed against more than 20 different molecular targets expressed on different cancers including EGFR, HER2, PSMA, CD25, GPC3, mesothelin, CD133, CD44, CEA, DLL3, PD-L1, and others [8].